Table 2 Details of DLI given to 318 patients in complete hematologic remission.
Entire cohort | PreDLI for mixed chimerism | PreDLI for MRD/molecular relapse | ProDLI | ||
|---|---|---|---|---|---|
Number | n (% of the entire cohort) | 318 (100%) | 169 (53.1%) | 23 (7.2%) | 126 (39.6%) |
Time alloSCT to first DLI | Median (min–max) [IQR] | 176 (15–1145) [132–260] | 190 (15–1145) [126–314] | 206 (42–589) [122.5–397] | 169 (30–606) [139.2–210.2] |
CD3+ cell/kg at first DLI (×106/kg) | Median (min–max) [IQR] | 1 (0.1–70) [1–10] | 1 (0.1–70) [1–3] | 1 (0.1-70) [1–10] | 1 (0.1–70) [0.5-10] |
Missing | 33 | 18 | 1 | 14 | |
Groups according to CD3+ dose at first DLI (×106/kg) | <1 | 65 (22.8%) | 29 (19.2%) | 5 (22.7%) | 31 (27.7%) |
1–5 | 128 (44.9%) | 86 (57%) | 8 (36.4%) | 34 (30.4%) | |
≥5 | 92 (32.3%) | 36 (23.8%) | 9 (40.9%) | 47 (42%) | |
Missing | 33 | 18 | 1 | 14 | |
Number of DLI infusion given | Median [IQR] | 2 [1–3] | 2 [1–3] | 3 [2–3.5] | 1 [1–3] |
Time DLI1–2 if 2 DLI (days) | Median (min–max) [IQR] | 36 (6–193) [32–48] | 71.5 (7–521) [34–126.2] | 42 (6–294) [33–62.5] | 43.5 (12–2422) [32.2–73.5] |
Time DLI2–3 if 3 DLI (days) | Median (min–max) [IQR] | 42 (14–326) [34–63.5] | 43.5 (8–516) [28–99.2] | 47 (14–326) [38–89.5] | 43 (29–459) [41–64] |
Stopped of immunosuppressive medication before DLI | No | 42 (14.2%) | 29 (19.3%) | 5 (22.7%) | 8 (6.5%) |
Yes | 253 (85.8%) | 121 (80.7%) | 17 (77.3%) | 115 (93.5%) | |
Missing | 23 | 19 | 1 | 3 | |
Use of immunosuppressive prophylaxis after DLI | No | 280 (88.9%) | 143 (89.4%) | 22 (95.7%) | 115 (92.7%) |
Yes | 27 (8.6%) | 17 (10.6%) | 1 (4.3%) | 9 (7.3%) | |
Missing | 11 | 9 | 0 | 2 |
